Tag Archives: R&D

Will "Robust Pipeline" Yield More New Drugs?

By Jill Wechsler | Published: January 21, 2013
Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies. A report by the Analysis Group for the Pharmaceutical Research and Manufacturers of America (PhRMA) documents more than 5,000 new medicines in [...]
Posted in Biotech, FDA, R&D, Regulatory, leadership | Also tagged , , , , , | Leave a comment

Thinking of Phase IV Trials? Europe Might See Things Differently…

By Guest Blogger | Published: December 3, 2012
By Peter O’ Donnell. With the shadow cast by Mediator across Europe now receding to a focus on the French law courts, the European Union (EU) said in late November that its pharmacovigilance arrangements offer “one of the most advanced and comprehensive systems in the world”. Certainly the EU’s legislative framework has been significantly boosted over [...]
Posted in Europe, Global, Guest Blog, R&D | Also tagged , , , | Leave a comment

Pipeline Report Preview

By Reid Paul | Published: November 14, 2012
Posted in Advertising, Biotech, Europe, FDA, Gene therapy, Global, IP, R&D, Regulatory, Strategy, Video | Also tagged , , , , , , , , | Leave a comment

Open Innovation in Pharma: What Does It Mean?

By Guest Blogger | Published: September 25, 2012
There’s a lot of talk today about “open innovation” in business and research forums—but what exactly does it mean? How does open innovation as a concept apply to the pharma sector? Does it signal a change in the way pharma companies approach research and innovation? Roy F. Waldron reports. There are a number of highly innovative [...]
Posted in Strategy | Also tagged , | Leave a comment

Public Interest in Private Science: New Pathways to Measuring R&D Success

By William Looney | Published: August 8, 2012
Today’s big product story — the apparent end to a decade-long drought in the drug development pipeline — is the prep stage for tomorrow’s big policy question:  are industry R&D priorities in synch with the changing burden of disease?
Posted in FDA, R&D | Also tagged , , | Leave a comment